Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies

References

• Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 Jun 18;399(10343):2294–2308. doi: 10.1016/S0140-6736(22)00662-6
   PubMed Web of Science ®Google Scholar
• Westin JR, Oluwole OO, Kersten MJ, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023 Jul 13;389(2):148–157. doi: 10.1056/NEJMoa2301665
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. doi: 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Jacobson CA, Ghobadi A, et al. 5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (zuma-1). Blood. 2023 Feb 23. doi: 10.1182/blood.2022018893
   Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [Clinical Trial;Multicenter Study;Research Support, Non-U.S. Gov’t]. Lancet. 2020 Sep 19;396(10254):839–852. doi: 10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019 Jan 03;380(1):45–56. doi: 10.1056/NEJMoa1804980
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Locke FL, Ma L, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B-Cell lymphoma in the United States. Transplant Cell Ther. 2022 Sep;28(9):581.e1–581.
   PubMedGoogle Scholar
• Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020 20 Sep;38(27):3119–3128. doi: 10.1200/JCO.19.02104
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Locke FL, Ma L, et al. Effectiveness and safety of axicabtagene-ciloleucel and tisagenlecleucel for large B-cell lymphoma in the real-world setting: a systematic review and meta-analysis. 5th European CAR T-cell Meeting; 2023; Rotterdam NL.
   Google Scholar
• Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022 Sep 22;28(10):2145–2154. doi: 10.1038/s41591-022-01969-y
   PubMed Web of Science ®Google Scholar
• Kwon M, Iacoboni G, Reguera JL, et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2023 Jan 1;108(1):110–121.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Hwang WT, Nastoupil LJ, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022 Jul 16;28(10):669–676. doi: 10.1016/j.jtct.2022.07.011
   PubMedGoogle Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Mak. 2018;38(2):200–211. doi: 10.1177/0272989X17725740
   PubMed Web of Science ®Google Scholar
• Maloney DG, Kuruvilla J, Liu FF, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021 Dec;14(1). doi: 10.1186/s13045-021-01144-9
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Chen JM, Chan K, et al. ABCL-289: matching-adjusted indirect comparison (maic) of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) in relapsed or refractory (r/r) large b-cell lymphoma (lbcl) after two or more prior lines of therapy [conference abstract]. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(Supplement 1):S388.
   Google Scholar
• Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care. 2008;24(2):170–177. doi: 10.1017/S0266462308080240
   PubMed Web of Science ®Google Scholar
• Banerjee R, Midha S, Kelkar AH, et al. Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. Br J Haematol. 2022 Mar;196(5):1274–1277.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017 Aug 03;130(16):1800–1808. doi: 10.1182/blood-2017-03-769620
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021 Oct 26;5(20):4149–4155. doi: 10.1182/bloodadvances.2020003848
   PubMed Web of Science ®Google Scholar
• Methley AM, Campbell S, Chew-Graham C, et al. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014 Nov 21;14(1):579. doi: 10.1186/s12913-014-0579-0
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 Jul 23;339(jul21 1):b2700. doi: 10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar
• Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute; 2011. p. 1–12.
   Google Scholar
• Salanti GH, Ades AE, Ioannidis JPA. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008;17(3):279–301. doi: 10.1177/0962280207080643 Stat Methods Med Res.
   PubMed Web of Science ®Google Scholar
• Lu GA, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc. 2006;101(474):447–459. doi: 10.1198/016214505000001302 J Am Stat Assoc.
   Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London (UK): National Institute for Health and Clinical Excellence; 2011.
   Google Scholar
• Macaskill P, Gatsonis C, Deeks JJ, et al. Chapter 10: Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C, editors. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0. The Cochrane Collaboration; 2010. http://srdta.cochrane.org/
   Google Scholar
• Maziarz RT, Zhang J, Yang H, et al. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2022 Apr 26;6(8):2536–2547. doi: 10.1182/bloodadvances.2021006280
   PubMed Web of Science ®Google Scholar
• Salles G, Spin P, Liu FF, et al. Indirect treatment comparison of liso-cel vs. salvage chemotherapy in diffuse large B-Cell lymphoma: transcend vs. scholar-1 [research support, non-U.S. Gov’t]. Adv Ther. 2021, 06;386: 3266–3280. doi: 10.1007/s12325-021-01756-0
   PubMed Web of Science ®Google Scholar
• Cartron G, Fox CP, Liu FF, et al. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Exp Hematol Oncol. 2022 Dec;11(1). no pagination. doi: 10.1186/s40164-022-00268-z
   PubMed Web of Science ®Google Scholar
• Maloney DG, Kuruvilla J, Liu FF, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma [clinical trial, phase i;comparative study; multicenter study; research support, non-U.S. Gov’t]. J Hematol Oncol. 2021 Sep 08;14(1):140. doi: 10.1186/s13045-021-01144-9
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020 Sep;26(9):1581–1588.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Chen JMH, Chan K, et al. Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leukemia Lymphoma. 2022;63(13):3052–3062. doi: 10.1080/10428194.2022.2113526
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Zhang J, Yang H, et al. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. Leukemia Lymphoma. 2022;63(4):845–854. doi: 10.1080/10428194.2021.2010069
   PubMed Web of Science ®Google Scholar
• Van DNE, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study. Bone Marrow Transplant. 2016 [cited 2015 Sep 14];51(1):51–57. doi: 10.1038/bmt.2015.213
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 Jul 26;28(27):4184–4190. doi: 10.1200/JCO.2010.28.1618
   PubMed Web of Science ®Google Scholar
• Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial [clinical trial, phase i; clinical trial, phase ii; multicenter study; research support, n.i.h. extramural; research support, non-U.S. Gov’t]. Lancet Oncol. 2019 01;20(1):31–42. doi: 10.1016/S1470-2045(18)30864-7
   PubMed Web of Science ®Google Scholar
• Gao J, Dahiya S, Patel SA. Challenges and solutions to superior chimeric antigen receptor-T design and deployment for B-cell lymphomas. Br J Haematol. 2023 Oct;203(2):161–168. doi: 10.1111/bjh.19001
   PubMedGoogle Scholar
• Evans SR. Fundamentals of clinical trial design. J Exp Stroke Transl Med. 2010 Jan 1;3(1):19–27. doi: 10.6030/1939-067X-3.1.19
   PubMedGoogle Scholar
• Bethge WA, Martus P, Schmitt M, et al. GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. 2022:22. doi: 10.1182/blood.2021015209
   Google Scholar
• Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am J Hematol. 2021 Oct 1;96(10):1295–1312. doi: 10.1002/ajh.26301
   PubMed Web of Science ®Google Scholar
• Locke FL, Hu Z, Siddiqi T, et al. Real-world impact of time from leukapheresis to infusion (vein-to-vein time) in patients with relapsed or refractory (r/r) large B-cell lymphoma (lbcl) treated with axicabtagene ciloleucel. Blood. 2022;140(Supplement 1):7512–7515. doi: 10.1182/blood-2022-155603
   Google Scholar
• Buecklein VL, Perez-Perez A, Rejeski K, et al. Inferior outcomes of EU Vs. US patients with relapsed/refractory large B-Cell Lymphoma after CD19 CAR T-Cell therapy are associated with differences in tumor burden, systemic inflammation, bridging therapy utilization and CAR-T product selection. ASH. Blood. 2022;140(Supplement 1):2411–2413. doi: 10.1182/blood-2022-165452
   Google Scholar
• Cartron G, Fox CP, Liu FF, et al. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. Exp Hematol Oncol. 2022;11(1). doi: 10.1186/s40164-022-00268-z
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Zhang J, Yang H, et al. ABCL-166: tisagenlecleucel and lisocabtagene maraleucel: comparative efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma [conference abstract]. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(Supplement 1):S380–S381.
   Google Scholar